Hydralazine was administered acutely to 12 patients who had pulmonary arterial hypertension of unknown cause. All of the patients were studied at rest and nine during exercise. On the basis of hydralazine response at rest, the patients were divided in two groups. In six patients (group A), pulmonary arteriolar resistance (Rp) decreased from 8.4 ± 1.4 to 4.8 ± 1.4 U/in (p < 0.001), cardiac index (CI) increased from 3.47 i 0.3 to 5.86 ± 0.5 1/min/m' (p < 0.005) and systemic resistance (Rs) decreased from 25 4 to 14 ± 2 U/mi (p < 0.01). The Rp/Rs ratio did not change significantly after hydralazine (0.32 ± 0.03 vs 0.33 ± 0.07, NS). In the other six patients (group B), Rs decreased from 25 ± 2 to 17.0 ± 1 U/mi (p < 0.01), but the other variables did not change significantly. Our results suggest that the pulmonary vasodilatory effect of hydralazine caused a marked reduction in right ventricular afterload in group A. In group B, a marked systemic vasodilatory effect occurred and right ventricular afterload was not reduced. On the basis of the previous hemodynamic response, only group A patients were treated with oral hydralazine (50 mg every 6 hours). Hemodynamic measurements were repeated 48 hours after hydralazine, both at rest and during exercise, as well as 8 months later in five of the six patients in whom the beneficial hemodynamic effects persisted. These data suggest that hydralazine can reduce Rp in selected patients (pulmonary arterial pressure < 60 mm Hg, Rp < 15 U/Mi and Rp/Rs ratio < 0.7) with pulmonary hypertension of unknown cause.
PULMONARY arterial hypertension of unknown cause (PAH-UC) is a challenging problem. Several reports indicate that vasodilator therapy may be beneficial in patients with PAH-UC. [1] [2] [3] [4] [5] The data suggest that the pulmonary vasculature in such patients is capable of dilatation, and that vasodilator therapy can be used to treat some patients. In patients with a favorable cardiopulmonary response, vasodilator therapy will be justified until there is proof of deleterious effects or until specific therapy is available. 5 Hydralazine has been shown to be beneficial for the chronic treatment of patients with PAH-UC.4 Because there is little experience with hydralazine in treating PAH-UC, and further testing of patients for responsiveness to this drug seems warranted, we investigated its effect in 12 patients who had PAH-UC with different degrees of pulmonary arterial pressure. We evaluated the hemodynamic effects of acute i.v. hydralazine in 12 patients at rest and in nine of the 12 during exercise. In six patients, the hemodynamic changes after oral hydralazine were recorded at 48 hours, both at rest and during exercise. In five of the six patients, the hemodynamic measurements were repeated after 8 months of hydralazine therapy.
Methods

Patients
Twelve patients who had PAH-UC were evaluated between January 1980 and January 1981. The diagnosis of PAH-UC was made after excluding diseases capable of producing PAH.W All patients were born and raised at an altitude of 2240 meters and were residents of Mexico City. Seven females and five males, ages 8-32 years (mean 25 years), were studied. At the time of the studies, they had been symptomatic for an average of 7 years (range 2-12 years). All had a history of dyspnea on exertion. Patients 2, 4, 5, 6, 8, 9, 10, 11 and 12) had a history of syncope. Patients 6, 8 and 10 had chest pain on exertion. All had clinical signs of PAH, electrocardiographic evidence of right ventricular enlargement, and radiologic signs of PAH.6 Patients in cardiac failure or with a respiratory infection were excluded. However, patients 6, 7 and 8 had been in cardiac failure, but recovered 6-8 months before the study. None had evidence of moderate or severe obstructive or restrictive lung disease by radiography or pulmonary function tests. Our 645 protocol was approved by the local committee for clinical investigation. All the procedures were explained to the patients or their parents, and their consent was obtained. Patient 2 underwent a lung biopsy and two patients were autopsied. Patient 6 died 2 weeks after the initial study and patient 8, 4 months later. In all of these patients, light microscopy showed the histopathologic spectrum of PAH-UC.7 No cardiac defects were found.
All medications were suspended in the ward 1 week before the study. Patients 2, 4, 8 and 10 were previously evaluated with isoproterenol. Patients 2 and 4 were receiving long-term sublingual isoproterenol. Patients 8 and 10 did not respond to isoproterenol.5
All patients had had a hemodynamic study in which no significant reduction in pulmonary arteriolar resistance was observed after 20 minutes of breathing 99.6% oxygen (before 15.9 ± 3, after 14.4 ± 2 U/M2, NS).
Hemodynamic Measurements
Our procedure for cardiac catheterization at rest has been described elsewhere.5 In brief, cardiac output (CO) was measured by the thermodilution method, and pressures were obtained by Swan-Ganz catheter. Standard formulas were used to calculate cardiac index (CI), right ventricular work index (RVWI), pulmonary arteriolar resistance (Rp), systemic resistance (Rs) and the left ventricular work index (LVWI). We also calculated the Rp/Rs and mean pulmonary/mean systemic pressure (PAP/SAP) ratios.
Exercise Testing
Patients were familiarized with the exercise technique. After control measurements, supine exercise tests were performed as described by Bronfin et al.9 All pressures were recorded continuously except during collection of blood samples. Blood and air samples were collected simultaneously, and CO was measured during the final minute of exercise. This degree of exercise increases total body oxygen consumption at rest at least twofold.10' Hydralazine Therapy After obtaining baseline hemodynamic measurements at rest in all patients and during exercise in nine, i.v. hydralazine, 0.33 mg/kg, was infused into the pulmonary artery over 3 minutes.
PAP and SAP were recorded continuously except during the collection of blood samples. CO was measured every 10 minutes. Exercise tests were performed in nine out of the 12 patients after a significant and steady increase in CO was observed. Only after the analysis of the response of the pulmonary and systemic circulation to the i.v. infusion of hydralazine was the drug continued orally. In patients 1-6, hydralazine had a beneficial vasodilator effect on the pulmonary circulation (group A). Although patients 9 and 12 showed a marked increase in CI during hydralazine, they were placed in group B: patient 9 increase in both RVWI and LVWI and patient 12 had a very severe increase in RVWI. After 6 hours of i.v. hydralazine, 50 mg of the drug was administered orally, and the hemodynamic measurements at rest and during exercise were repeated 48 hours later.
Before each dose of hydralazine, pulse rates in the supine and standing positions and blood pressures were monitored.
Group A patients were discharged on hydralazine (50 mg every 6 hours) and five of the six patients returned 8 months after the initial evaluation for repeat right-heart catheterization to determine whether the initial hemodynamic changes had persisted. The last dose of hydralazine was always given 1-2 hours before cardiac catheterization.
Statistical analysis and significance of results were calculated using standard methods for calculation of standard and paired t tests. All results were expressed as the mean ± SEM.12
Results
Hemodynamic Data at Rest (table 1) All 12 patients had elevated PAP and Rp. In group A, PAP was less than 50 mm Hg, Rp was less than 15 U/M2, Rp/Rs less than 0.45 and PAP/SAP less than 0.55. In group B, PAP was greater than 60 mm Hg, Rp greater, than 15 U/M2, Rp/Rs greater than 0.72 and PAP/SAP greater than 0.80. Pulmonary wedge pressure at rest was normal in all patients. After the infusion of hydralazine into the pulmonary artery in group A, Rp (p < 0.001) and Rs (p < 0.01) decreased and mean PAP did not change. There were statistically significant increases in heart rate (p < 0.05) and CI (p < 0.005). In group B, RVWI increased (p < 0.05).
Hemodynamic Data During Exercise (table 2) Although CI increased with exercise relative to control values, after hydralazine therapy it was significantly increased during exercise (p < 0.005).
The same response was shown for heart rate (p < 0.05) and for oxygen consumption (p < 0.05).
PAP increased in the nine patients studied during exercise; this increase was not blunted by hydralazine for the whole group. The increase in Rp during exercise was significantly blunted by hydralazine (p < 0.001). The duration of exercise varied according to the level of PAP (range 4-7 minutes). During exercise, all patients had exertional dyspnea and fatigue, but no other symptoms. The increase in oxygen consumption after hydralazine was due to an increase in the level of exercise.
Hemodynamic Differences (table 3) At rest, group A patients had lower PAP (p < 0.005), Rp (p < 0.05), Rp/Rs (p < 0.005), PAP/SAP (p < 0.001) and RVWI (p < 0.05) than group B patients. After i.v. hydralazine in group A, Rp decreased by 40%, but remained approximately 2 U above the normal value. The Rp/Rs and PAP/SAP ratios did not change significantly. Compared with had a worsening in blood gas exchange and a marked 646 CIRCULATION group A, group B had a significant increase in PAP After hydralazine, PAP was not statistically different from control. Pulmonary arteriolar resistance decreased (p < 0.005) and CI increased (p < 0.01). The hemodynamic data during exercise show that in group A, hydralazine blunted the increases in PAP (p < 0.05) and in Rp (p < 0.005) that occurred in the absence of the drug. After chronic administration of hydralazine (8 months), pulmonary hemodynamics had not changed in five patients.
Clinical Response, Complications and Follow-up
The patients who continued to take hydralazine during the follow-up period (8 months) showed beneficial symptomatic effect and relief of dyspnea on exertion; patients 2 and 4 have not had syncope. During the first 24 hours after the initiation of hydralazine, two patients had nausea and headache, which disappeared with continued therapy. No patient had postural hypotension or any clinical manifestation of a lupus-like syndrome.
Discussion
Although our patients were all raised and lived at an altitude of 2240 meters, we do not believe that this factor influences the clinical picture. The lack of response to oxygen breathing tends to support the idea that relative alveolar hypoxia does not make our patients clinically different from those who have the disease elsewhere.
Effect of Hydralazine in Pulmonary Circulation
Recent reports show that hydralazine has a pulmonary vasodilatory effect in the arteriolar bed of the lung.4 '3 Our findings support these observations. Both at rest and during exercise, CI increased markedly, without an appreciable change in the capillary wedge pressure after hydralazine, leading to decreased pulmonary arteriolar resistance. However, decreased Rp could be due to active pulmonary vasodilation or to the increased CI, which also causes dilation of the pulmonary vascular bed. An increased CI could not be due to the known effect of hydralazine on the myocardium, which is only seen at higher doses than those used in conventional therapy."' 15 The improvement in CI could result from a decrease in left ventricular afterload associated with an increase in heart rate, as a result of sympathetic response to systemic vasodilation or to the known primary effect of hydralazine on the sinus node.'6 Although a direct effect (active pulmonary vasodilation) of hydralazine seems likely, an indirect action cannot be ruled out. The final effect is that hydralazine could lead to a reduction in right ventricular afterload.
The Response of the Pulmonary Circulation to Hydralazine in PAH-UC Patients Two types of response were observed. Group B patients had an unfavorable hemodynamic response, characterized by a positive chronotropic action of hydralazine on the heart. Rp remained fourfold above the normal values. The Rp/Rs and PAP/SAP ratios, which were greater than 0.7 at control, increased because of a significant decrease in Rs, which reflects a dominant hydralazine effect on the systemic circulation. The nonsignificant increase in CI in group B patients cannot be attributed to a reduction in the right ventricular afterload, but it can be attributed to the increase in heart rate due to sympathetic response to systemic vasodilatation, to passive distention of the pulmonary arteriolar bed, and perhaps to a lesser degree of active pulmonary vasodilatation. This minor response in group B patients might be due to more advanced anatomic changes in the pulmonary vasculature. Therefore, these patients represent a later phase of this disease process, at which time they are unresponsive.
PAH-UC patients with PAP greater than 70 mm Hg, Rp greater than 15 U/M2, Rp/Rs greater than 0.7 and PAP/SAP greater than 0.8 do not seem to have an important component of PAH that can be reversed with hydralazine. These observations are similar to those reported with isoproterenol in PAH-UC patients who have similar hemodynamic profiles.5 Therefore, a favorable response with pulmonary vasodilator drugs in PAH-UC patients at this stage of the disease seems unlikely.
When the heart rate and CI increase, followed by a significant decrease of Rp to normal or nearly normal values, hydralazine may have a favorable effect on the pulmonary circulation. This possibility is reinforced by the behavior of the Rp/Rs and PAP/SAP ratios. If these ratios remain the same or close to the control despite a significant decrease in Rs, a marked vasodilator effect of the drug in the pulmonary circulation is suggested. A significant decrease in Rp led to a reduction in right ventricular afterload and in- creased output from the right ventricular chamber. Therefore, hydralazine might counteract the vasoconstriction of the pulmonary vessels in PAH-UC patients with PAP less than 60 mm Hg, Rp less than 15 U/M2 and Rp/Rs and PAP/SAP ratios less than 0.7. These data are in agreement with data from a previous study in which hydralazine was used in these patients. 4 The beneficial hemodynamic effect was present after 8 months of oral therapy. Hydralazine also provides symptomatic benefit. However, despite an important component of pulmonary arteriolar constriction, reversed by hydralazine, progression of the underlying disease seems likely. Patient 6 died suddenly, although her effort tolerance had improved and syncope had disappeared.
Cross-reactivity with Isoproterenol
All patients should be tested with pulmonary vasodilators to determine whether such treatment is likely to be beneficial. However, it is possible to predict or suspect which patients will not respond to vasodilator therapy (group B patients). Our previously reported hemodynamic data for isoproterenol in PAH-UC5 and the data obtained with hydralazine in four of the patients showed cross-reactivity between these two pulmonary vasodilator drugs. Our hemodynamic data on oral and i.v. hydralazine are similar. A trial of i.v. hydralazine could be the most feasible way to select PAH-UC patients suitable for chronic oral treatment.
In conclusion, our study shows that oral hydralazine is an effective pulmonary vasodilator for selected patients with PAH-UC. It can relieve symptoms with minimal side effects. Whether the use of hydralazine will alter the course of PAH-UC is not known. A prolonged follow-up is required to better understand its role in PAH-UC. Chronic hydralazine is justified in patients who have a favorable hemodynamic response to acute administration.
